Preparation method of targeted thrombolytic microcapsules

A thrombolytic and targeting technology, applied in the field of preparation of targeted thrombolytic microcapsules, can solve problems such as adverse effects on healthy parts, achieve excellent thrombolytic performance, stable surface structure, simple preparation method and process

Inactive Publication Date: 2020-01-10
HUAIYIN INSTITUTE OF TECHNOLOGY
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Drugs will enter various organs of the human body along with the blood, and the randomness of drug distribution may cause adverse effects on healthy parts

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of targeted thrombolytic microcapsules
  • Preparation method of targeted thrombolytic microcapsules
  • Preparation method of targeted thrombolytic microcapsules

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0023] like Figure 1-3 As shown, a preparation method of targeted thrombolytic microcapsules, comprising the following steps:

[0024] 1) adding soluble microspheres as the inner core to the dopamine solution, and preparing composite microspheres with polydopamine as the shell through surface autoxidative polymerization;

[0025] 2) The polydopamine-modified composite microspheres are further obtained through the reaction of dopamine and platelet ligand protein to obtain active biological protein-modified microspheres;

[0026] 3) Dissolving and etching the prepared active bioprotein-modified microspheres through an organic solvent to obtain a hollow microcapsule structure capable of loading drugs, and then obtain targeted functional thrombolytic microspheres by loading thrombolytic drugs .

[0027] In step 1), 1-100 μg of soluble microspheres with a diameter of 500nm-5 μm are dispersed in 20-500 mL of Tris-HCl buffer solution, and the concentration range of soluble microsp...

Embodiment 1

[0036] 1) The preparation of core-shell microparticles comprises the following steps: disperse 100 μg of polyimide microspheres with a diameter of 500 nm in 50 mL of Tris / HCl buffer solution, and stir for 0.5 h at 25 degrees Celsius. Subsequently, 100 mg of dopamine was added to the above solution, stirred at 25 degrees Celsius for 6 hours, and centrifuged at 1000 r / min after the reaction to obtain polydopamine-modified polyimide microspheres.

[0037] 2) The step of biofunctionalization of the particle surface is as follows: disperse the polydopamine-modified microspheres obtained above in a PBS buffer solution in which fibrinogen is dissolved at a concentration of 1 mg / ml, and react at room temperature for 2 hours to make the fibrinogen Modified to the surface of polydopamine, then freeze-dried at 1000r / min for 6h to obtain surface protein-modified particles.

[0038] 3) The preparation steps of the microcapsules are as follows: take 1 g of the above-mentioned particles and ...

Embodiment 2

[0042] 1) Preparation of microparticles with core-shell structure, the steps are: disperse 100 μg of polystyrene microspheres with a diameter of 500 nm in 50 mL of Tris / HCl buffer solution, and stir for 0.5 h at 25 degrees Celsius. Subsequently, 100 mg of dopamine was added to the above solution, stirred at 25 degrees Celsius for 6 hours, and centrifuged at 1000 r / min after the reaction to obtain polydopamine-modified polystyrene microspheres.

[0043] 2) The step of biofunctionalization of the particle surface is as follows: disperse the polydopamine-modified microspheres obtained above in a PBS buffer solution in which fibrinogen is dissolved at a concentration of 1 mg / ml, and react at room temperature for 2 hours to make the fibrinogen Modified to the surface of polydopamine, then freeze-dried at 1000r / min for 6h to obtain surface protein-modified particles.

[0044] 3) The preparation steps of the microcapsules are as follows: take 1 g of the above-mentioned particles and ad...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Diameteraaaaaaaaaa
Concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses a preparation method of targeted thrombolytic microcapsules, which belongs to the technical field of biological materials, the method and comprises the following steps: 1) adding soluble microspheres serving as inner cores into a dopamine solution to prepare polydopamine modified microspheres; 2) further reacting the polydopamine modified microsphere with platelet ligand protein to obtain the active biological protein modified microspheres; and 3) dissolving and etching the microsphere core of the prepared microsphere through a proper mild solvent to obtain the hollow microcapsule structure capable of loading a drug, and then loading thrombolytic drugs to obtain the thrombolytic microspheres with the targeting function. Through surface modification and solvent etching technologies, the drug-loaded hollow microcapsule with good biocompatibility is prepared, and meanwhile, the preparation method and process are simple, the surface structure is stable, and excellent thrombolysis performance, blood compatibility and practicability are achieved.

Description

technical field [0001] The invention belongs to the technical field of biological materials, and in particular relates to a preparation method of targeted thrombolytic microcapsules. Background technique [0002] The sudden onset of cardiovascular and cerebrovascular diseases will cut off the normal blood supply of important organs and tissues such as the heart, lungs and brain. The current antithrombotic drugs are mainly divided into oral and intravenous drugs. Drugs will enter various organs of the human body along with the blood, and the randomness of drug distribution may cause adverse effects on healthy parts. Through the design of the anticoagulant drug carrier, it is targeted to the activated platelet, and then the drug is released around the activated platelet. That is, the adhesion of platelets at the interface can be inhibited, and the damage to normal parts can be reduced. [0003] The formation of thrombus mainly includes a series of complex processes such as p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/50A61K47/34A61K47/42A61K45/00A61P7/02
CPCA61K9/5031A61K9/5052A61K45/00A61P7/02
Inventor 叶玮王囡柏伟刘静静张超柳森刘爱辉丁红燕
Owner HUAIYIN INSTITUTE OF TECHNOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap